CIPLA.NS - Cipla Limited

NSE - NSE Real Time Price. Currency in INR
+3.05 (+0.51%)
At close: 3:29PM IST
Stock chart is not supported by your current browser
Previous close600.40
Bid621.40 x 0
Ask0.00 x 0
Day's range592.00 - 606.10
52-week range480.20 - 663.40
Avg. volume1,339,146
Market cap485.774B
PE ratio (TTM)41.57
EPS (TTM)14.52
Earnings dateN/A
Forward dividend & yield2.00 (0.33%)
Ex-dividend date2017-07-26
1y target est645.38
  • Reuters13 days ago

    Cipla third-quarter profit rises, but below estimates

    Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates. Net profit attributable to shareholders ...

  • Reuters3 months ago

    Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

    Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday. Drugmakers Lupin Ltd and ...

  • IANS6 months ago

    Equity indices recover from 5-week lows, global cues lift sentiments

    Mumbai, Aug 14 (IANS) Broadly positive global cues, coupled with healthy buying in consumer durables, metals and automobile stocks, lifted the key Indian equity indices from their five-week lows to trade ...

  • Reuters6 months ago

    Cipla first-quarter profit rises 20 percent, beats estimates

    Cipla Ltd, India's fourth-largest drugmaker by sales, reported a 20 percent rise in quarterly profit, beating analysts' estimates, as higher sales in Europe and South Africa offset weakness in its key domestic market. Revenue from South Africa, Cipla's third largest market, rose 21 percent to 4.88 billion rupees ($76.03 million) compared with last year while Europe revenues climbed 33 percent to 1.58 billion rupees. India revenues fell 13 percent to 12.71 billion rupees, impacted by a nationwide tax reform.

  • Reuters9 months ago

    Cipla lowers bio drugs investment, sharpens focus on respiratory

    Cipla Ltd (CIPL.NS), India's fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products, the company's chief executive said on Thursday. It has put plans to build a biotech plant in South Africa, its third-largest market, on hold, and will soon start looking for partners for its existing biosimilars programme, CEO Umang Vohra said at a press conference. The move signals a shift in Cipla's strategy from just three years ago, when Chairman and founder Yusuf Hamied said the company aimed to replicate its success at launching cut-price AIDS drugs in Africa in 2001 with cheap biosimilars.

  • IANS11 months ago

    Cipla gets US regulatory nod for generic Epzicom tablets

    Mumbai, April 4 (IANS) Global pharmaceutical company Cipla on Tuesday announced that it has received final approval of the US Food and Drug Administration (USFDA) for the generic version of Epzicom tablets ...